NASDAQ:CRVS Corvus Pharmaceuticals Q1 2026 Earnings Report $11.62 -0.18 (-1.53%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$11.64 +0.02 (+0.17%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Corvus Pharmaceuticals EPS ResultsActual EPS-$0.15Consensus EPS -$0.14Beat/MissMissed by -$0.01One Year Ago EPSN/ACorvus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACorvus Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateThursday, May 7, 2026Conference Call Time4:00PM ETUpcoming EarningsCorvus Pharmaceuticals' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Corvus Pharmaceuticals Earnings HeadlinesCorvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?September 25 at 1:36 PM | finance.yahoo.comCRVS Share News TodaySeptember 17, 2026 | uk.investing.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comCorvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis TreatmentAugust 27, 2026 | seekingalpha.comCorvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma TrialAugust 27, 2026 | finance.yahoo.comSee More Corvus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corvus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corvus Pharmaceuticals and other key companies, straight to your email. Email Address About Corvus PharmaceuticalsCorvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the immune system to treat cancer and other serious diseases. The company’s research is centered on small-molecule and antibody-based therapies designed to influence immune-cell activity and improve the body’s ability to respond to disease. Corvus’ lead investigational product is soquelitinib, also known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK). The company is studying soquelitinib as a potential treatment for T-cell lymphomas and other conditions in which targeted modulation of T-cell activity may provide a therapeutic benefit. As an investigational medicine, soquelitinib has not been approved for general commercial use. Founded in 2014 and headquartered in Burlingame, California, Corvus Pharmaceuticals advances its programs through clinical development and collaborations serving global pharmaceutical and biotechnology markets. The company is led by Richard A. Miller, who serves as president and chief executive officer.View Corvus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
